New Stock News | The prospectus for the listing of Lianchi Hospital in Hong Kong has become invalid.
Lotus Lake Hospital Group Co., Ltd. (referred to as Lotus Lake Hospital) submitted its Hong Kong stock prospectus on January 13, 2026, which expired after 6 months on July 13, 2026.
Lianchi Hospital Group Co., Ltd. (referred to as Lianchi Hospital) submitted its Hong Kong IPO prospectus on January 13, 2026, which expired 6 months later on July 13, 2026. China Galaxy International is its exclusive sponsor.
According to the previous prospectus, Lianchi Hospital is a Chinese specialty boutique medical group. As of September 30, 2025, Lianchi Hospital operates 5 hospitals and one nursing home under a centralized management structure. According to Frost & Sullivan data, based on the volume of private hospital knee surgery in 2024, the company's Zibo Lianchi Orthopedic Hospital ranks first in Shandong Province and third nationwide. According to Frost & Sullivan data, based on revenue in 2024, the company's Chongqing Great Wall Orthopedic Hospital ranks first among private orthopedic specialty hospitals in southwest China.
Related Articles
ABBISKO-B(02256): Hoya Pharmaceuticals announced that the new oral small molecule pan-KRAS inhibitor ABSK211 has received FDA approval for clinical trial application.
.png)
INSILICO (03696) and CMS (00867) have reached a new strategic partnership in the field of central nervous system drug development.
BEKE-W(02423) spent about 5 million dollars to repurchase 958,800 shares on July 10th.
ABBISKO-B(02256): Hoya Pharmaceuticals announced that the new oral small molecule pan-KRAS inhibitor ABSK211 has received FDA approval for clinical trial application.
INSILICO (03696) and CMS (00867) have reached a new strategic partnership in the field of central nervous system drug development.
BEKE-W(02423) spent about 5 million dollars to repurchase 958,800 shares on July 10th.
RECOMMEND
